최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기韓國營養學會誌 = The Korean journal of nutrition., v.41 no.1, 2008년, pp.31 - 40
강미란 (연세대학교 노화과학협동과정) , 김지영 (연세대학교 임상영양유전 국가지정연구실) , 현예정 (연세대학교 임상영양유전 국가지정연구실) , 김혜진 (연세대학교 임상영양유전 국가지정연구실) , 여현양 (연세대학교 노화과학협동과정) , 송영득 (국민건강보험공단 일산병원 내분비내과) , 이종호 (연세대학교 임상영양유전 국가지정연구실)
This study was aimed at evaluating the effect of red-yeast-rice supplementation on cholesterol-lowering and glucose control in subjects with impaired fasting glucose (IFT) or impaired glucose tolerance (IGT). We conducted a doubleblind, placebo-controlled study with 3 groups; placebo, low dose group...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200
Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U. S.: 1990-1998. Diabetes Care 2000; 23: 1278-1283
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431
www.nso.go.kr
Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the inter99 study. Diabetes Care 2003; 26: 2335-2340
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290(4): 486-494
Bell PM. Clinical significance of insulin resistance. Diabet Med 1996; 13: 504-509
Patrick L, Uzick M. Cardiovascular Disease; C-reactive protein and the inflammatory Disease Paradigm: HMG-CoA reductase, Red yeast rice and Olive oil polyphenols. Altern Med Rev 2001; 6(3): 248-271
Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietaty Chinese red-yeastrice dietary supplement. Am J Clin Nutr 1999; 69: 231-236
Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang Decreases Serum Lipoprotein (a) and C-reactive Protein Concentrations in patients with Coronary Heart Disease. Clin Chem 2003; 49: 1347-1352
Yang HT, Lin SH, Huang SY, Chou HJ. A comparative Study of Xuezhikang and Mevalotin in treatment of Essential Hyperlipidemia. Chinese Journal of New Drugs 1997; 6: 265-268
Kuno N, Mizutani T. A Clinacal Study on treating Primary Hyperlipidemia with Xuezhikang. Chinese Circulation J 1997; 12: 16-19
Reaven GM. Insulin resistance, Hyperinsulinemia, Hypertriglyceridemia and hypertension: parallels between human disease and rodent models. Diabetes Care 1991; 14: 195-202
Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis risk in communities study): a cohort study. Lancet 1999; 353: 1649-1652
Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103(3): 357-362
Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M. Effects of simvastatin and atovastatin administration in insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150(1): 121-127
Pontrelli L. et al. Atorvastatin treatment beneficially alters the lipoprotein profile and increses low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002; 51(3): 334-342?
http://www.krra.or.kr
Wang J, Lu Z, Chi J, Wang W, Su M, Kou W, Y'u L, Chen L, Zhu JS, Chang J. Multicenter clinical trial of the serum lipidlowering effects of a Monascus purpureus (red yeast) rice preparation from traditional chinese medicine. Curr Ther Res Clin Exp 1997; 58: 964-977
Choi YS, Lee SY. Serum cholesterol and 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Korean Soc Food Sci Nutr 1992; 21(5): 580-593
Chang JC, Wu MC, Liu IM, Cheng JT. Plasma glucose-lowering action of Hon-Chi in Streptozotocin-induced diabetes rats. Horm Metab Res 2006; 38(2): 76-81
Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004; 58(10): 614-618
Satoh K, Keimatsu N, Kanda M, Kasai T, Takaguri A, Sun F, Ichihara K. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull 2005; 28(11): 2092-2095
Farrer M, Winocour PH, Evans K, Neil HA, Laker MF, Kesteven P, Alberti KG. Simvastatin in non-insulin dependent diabetes mellitus: effect on serum lipid, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994; 23: 111-119
Kawai T, Tokui M, Funae O, Meguro S, Yamada S, Tabata M, Shimada A. Efficacy of pitavastatin, a New HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care 2005;28(12): 2980-2981
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.